Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL)

Next Previous
X
Search
Trial Profile

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin

    • Most Recent Events

    • 31 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Results ( n=38) presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top